



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|-----------------|-------------|----------------------|---------------------|------------------|
| 09/856,662 | 05/24/2001 | Toyoki Moribe | 0032-0261P | 3176 |

7590 01/07/2003

Birch Stewart Kolasch & Birch
PO Box 747
Falls Church, VA 22040-0747

EXAMINER

ALLEN, MARIANNE P

| ART UNIT | PAPER NUMBER |
|----------|--------------|
|----------|--------------|

1631

DATE MAILED: 01/07/2003

10

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

Address: ASSISTANT COMMISSIONER FOR PATENTS

Washington, D.C. 20231

| | | | |
|---------------------------------|-------------|---|---------------------|
| APPLICATION NO./ CONTROL NO. | FILING DATE | FIRST NAMED INVENTOR / PATENT IN REEXAMINATION | ATTORNEY DOCKET NO. |
|---------------------------------|-------------|---|---------------------|

57/357162

| |
|----------|
| EXAMINER |
|----------|

| | |
|----------|-------|
| ART UNIT | PAPER |
|----------|-------|

10

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

The reply filed on 11/4/02 is not fully responsive to the prior Office Action because of the following omission(s) or matter(s): Applicant elected Group I with traverse and further elected the combination of SEQ ID NOS: 3, 86, 105, 106, and 113 for examination. However, the election of this combination of sequences is not understood. These SEQ ID NOS. do not appear to define disclosed primer pairs which can amplify all HLA-A alleles (for example) nor DNA probes which can specifically hybridize with the sequence of at least one specific HLA-A allele (for example). See claim 1. The specification does not appear to disclose this particular combination of sequences being used in the claimed method together. The specification does not appear to disclose a relationship among these five sequences. Note that neither of claims 8 or 9 recites all five sequences. The sequence election appears to be erroneous and clarification is requested. See 37 CFR 1.111. Since the above-mentioned reply appears to be *bona fide*, applicant is given **ONE (1) MONTH or THIRTY (30) DAYS** from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

Any inquiry concerning this communication should be directed to Marianne P. Allen at telephone number 703-308-0666.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward, can be reached on (703) 308-4028. The fax phone number for the organization where this application or proceeding is assigned is 703-305-3014.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Marianne P. Allen
MARIANNE P. ALLEN
PRIMARY EXAMINER
GROUP 1600
601631